Validated GeniePlex Panels
Validated GeniePlex panels customer applications
Reference compendium of GeniePlex multiplex immunoassay panels and their validated applications. Entries describe the application context, biological sample type, and analytes successfully measured.
Featured GeniePlex citations
Twelve peer-reviewed and preprint studies that explicitly cite the GeniePlex platform in their methods. These represent direct, attributable evidence of platform performance across cytometers, sample types, and analyte combinations.
| # | Species | Application & Citation | Sample / Cytometer | Analytes |
|---|---|---|---|---|
| F1 | Human | T-cell receptor signalling / TCR engineeringAl-Hourani et al. (2021) — bioRxiv preprint · PREPRINT | Cell culture supernatantMiltenyi MACSQuant | IFN-γ, IL-2, TNF-α |
| F2 | Human | Foreign body response / implantable medical devicesWard et al. (2024) — Acta Biomaterialia | Myofibroblast cell culture supernatantBD Accuri C6 Plus | Custom 5-plex: IL-1β, IL-10, IL-6, CTGF/CCN2, MCP-1/CCL2 |
| F3 | Mouse | Nanomedicine / metal-organic framework biocompatibilityZhuang et al. (2025) — Advanced Healthcare Materials | PlasmaBeckman Coulter CyAn ADP | Mouse Inflammation 17-plex (MOAMPM022) |
| F4 | Rat | Skeletal muscle pharmacologyMarciano et al. — Peer-reviewed | Muscle tissue homogenateBD Accuri C6 | Custom rat 8-plex |
| F5 | Mouse | Endothelial chromatin remodelling / inflammatory memorySpindola et al. (2025) — bioRxiv preprint · PREPRINT | Plasma + cell culture supernatantBD FACSymphony A3 | Mouse Inflammation 17-plex (MOAMPM022) |
| F6 | Mouse | Cancer immunotherapy / scaffold-mediated lentiviral deliveryDandia et al. — Peer-reviewed | Serum + cell culture supernatantBD FACSAria III | Th1 + Th17 (MOAMPM015): IL-2, IFN-γ, TNF-α, IL-17A, IL-21, IL-22 |
| F7 | Human | NK cell immunotherapy / ovarian cancer (TRAIL-engineered)Sheedy et al. (2024) — Heliyon | Ovarian cancer + NK cell co-culture supernatantBD FACS Canto II | Custom 4-plex: soluble TRAIL, IFN-γ, Granzyme A, Granzyme B |
| F8 | Mouse | Claudin-6 / breast cancer immunotherapyCorreia et al. — Cell Press (peer-reviewed) | Mouse serum (syngeneic tumour model)BD Accuri C6 | Mouse 3-plex (MOAMPM008): IL-6, IL-10, IL-2 |
| F9 | Human | Knee osteoarthritis pain / intra-articular biomarkersPuts et al. (2024) — Journal of Clinical Medicine | Synovial fluidNot disclosed | 11-plex (IL-6, IL-8, IL-10, TNF-α, CXCL-10, BDNF, NGF, CCL2, CCL5, VEGF, IL-1RI) + 3-plex (MMP-1, MMP-7, IL-1β) + single-plex CXCL-9 |
| F10 | Human | SARS-CoV-2 / monocyte-epithelial inflammatory regulationSimakou et al. (2024) — Discovery Immunology (OUP) | ALI bronchial epithelium + monocyte co-culture supernatantBD LSR Fortessa | Custom 14-plex (largest in dataset): M-CSF, CCL2, G-CSF, IFN-λ1, IL-8 + 9 more; also HUFI01701 (PROS1 singleplex) |
| F11 | Mouse | NAFLD/NASH liver disease modelling / drug screeningvan Os et al. (2022) — Biomaterials | 3D multicellular liver spheroid supernatantBD FACSAria II | Mouse Inflammation 5-plex Panel 1 (MOAMPM016): IL-6, TNF-α, MCP-1 + 2 more |
| F12 | Mouse | Alzheimer's / glial neuroinflammation (CK2 inhibition)Da Silva et al. (2025) — bioRxiv preprint · PREPRINT | Brain tissue homogenate (cortex + hippocampus)BD FACSymphony A3 | Mouse Inflammation 7-plex Panel 1 (MOAMPM019): IL-6, MCP-1, IP-10, KC, TNF-α + 2 more |
Validated panel reference
Panel configurations and validated applications. All configurations can be ordered as off-the-shelf or custom multiplex kits.
| # | Species | Application Area | Sample Type | Analytes Validated |
|---|---|---|---|---|
| 1 | Human | Acute leukemia / cytokine prognostics | Serum | IFN-γ, IL-2, IL-4, IL-10, IL-17A, TNF-α |
| 2 | Human | Systemic lupus erythematosus (IFN signature) | Serum | IFN-γ |
| 3 | Human | Ménière's disease / stress-neuroendocrine axis | Serum | IL-6, TNF-α, G-CSF |
| 4 | Human | Reproductive immunology / recurrent implantation failure | Serum | IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, TNF-α, TNF-β, G-CSF, GM-CSF |
| 5 | Human | Pediatric ARDS / adenovirus infection | Serum | IL-2, IL-6, IL-8, IL-10, TNF-α, IFN-γ |
| 6 | Human | Lupus nephritis | Serum | IL-1β, IL-4, IL-6, IL-22, TNF-α, IFN-γ, MCP-1 |
| 7 | Human | Type 2 diabetes / diastolic dysfunction | Serum | IL-1α, IL-1β, IL-6, E-selectin |
| 8 | Human | Prediabetes / low-grade inflammation | Serum | E-selectin, VEGF-A, TNF-α, IL-1β, IL-6, IL-8, IL-18 |
| 9 | Human | Post-COVID syndrome (11-plex inflammation) | Serum | IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-27, IP-10, MCP-1, TNF-α |
| 10 | Human | Cardiovascular / inflammaging biomarker | Serum | GDF-15 |
| 11 | Human | Idiopathic pulmonary fibrosis | Serum | CCL18, CXCL13, VEGF-A, IL-8, IGFBP-1, IGFBP-2, IGFBP-7, MMP-1, MMP-9, MPO, ICAM-1 |
| 12 | Human | Pediatric MIS / multisystem inflammatory syndrome | Serum | IFN-γ, IL-1RA, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, TNF-α, MIP-1α, MCP-1, RANTES |
| 13 | Human | Th1/Th2/Th17 14-plex profiling (broad use) | Serum | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β |
| 14 | Human | Chronic hepatitis B / IP-10 response monitoring | Serum | IP-10 |
| 15 | Human | Severe COVID-19 / T cell therapy 5-plex | Serum | IFN-γ, IL-4, IL-6, IL-10, TNF-α |
| 16 | Human | Chronic hepatitis B / cytokine response profile | Serum | IFN-γ, IL-1β, IL-1RN, IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-17A, CCL2, CCL3, CCL5, CXCL8, CXCL10, TNF-α, CSF2 |
| 17 | Human | Scleroderma / pulmonary involvement | Serum | IL-1β, IL-4, IL-6, IL-22, TNF-α, IFN-γ |
| 18 | Human | Vaccine response / BBIBP-CorV SARS-CoV-2 | Serum | IFN-γ, IFN-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17A, TNF-α |
| 19 | Human | Th1/Th2 10-plex panel | Serum | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-α |
| 20 | Human | Multiple sclerosis / treatment response (ocrelizumab) | Serum | IL-6, IFN-γ, TNF-α, IL-1β, IL-12, IL-2, IL-4, IL-5, IL-10, IL-17A |
| 21 | Human | Preterm infants / hydrocortisone treatment 12-plex | Serum | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, TNF-α, TNF-β |
| 22 | Human | Multiple myeloma prognostic nomogram | Serum | MIP-1α, MIF, TNF-α, VEGF-α, MCP-1, IL-17A, IL-6, IL-21, IL-10 |
| 23 | Human | TEMPI syndrome / MIF profiling | Serum | MIF |
| 24 | Human | Pre/post-ictal innate immune profiling | Serum | IFN-γ, IL-1β, IL-1RA, IL-4, IL-6, IL-10, IL-12, IL-17, MCP-1, MIP-1α, TNF-α |
| 25 | Human | FADD deficiency / ALPS-FAS phenotyping | Serum | sFASL, IL-10, IL-18, sCD25 |
| 26 | Human | Cutaneous T-cell lymphoma | Serum | CCL21, CCL22 |
| 27 | Human | Pruritic urticarial papules of pregnancy 18-plex | Serum | GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, IL-33, TNF-α, TNF-β, TSLP |
| 28 | Human | Rickettsia japonica infection | Serum | IFN-γ, IL-12p70, TNF-α, IL-2, IL-8, IL-4, IL-5, IL-9, IL-33, IL-6, IL-17A, IL-17F, IL-22 |
| 29 | Human | Adenovirus pneumonia severity | Serum | IFN-γ, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-17F, IL-22, TNF-α, TNF-β |
| 30 | Human | Bullous pemphigoid severity | Serum + blister fluid | IL-16, IL-17A, IL-23p19 |
| 31 | Human | Treg / thyroid carcinoma | Serum | IL-10, IL-35 |
| 32 | Human | COPD / energy homeostasis | Serum | TNF-α, IL-6 |
| 33 | Human | Air pollution / atherosclerotic plaque biomarkers | Serum | MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, TIMP-1, TIMP-2, sCD40L, sCD62P, sRAGE, IL-1β, CRP, MIP-1α, MIP-1β, IGF-1, IGFBP-1, IGFBP-3 |
| 34 | Human | Fanconi anemia / NK cell hyperinflammation | Serum | IL-2, IL-4, IL-6, IL-7, IL-10, IL-15, IL-12p40, IFN-γ, TNF-α, GM-CSF, MIP-1α, MIP-1β, MCP-1, IP-10/CXCL10 |
| 35 | Human | Asthma phenotyping / Th2/Th17 | Serum | IL-4, IL-5, IL-13, IL-6, IL-17A, IL-23, TGF-β1 |
| 36 | Human | HLH vs severe viral infection discrimination | Serum | IFN-γ, TNF-α, IL-12p40, IL-4, IL-6, IL-10, GM-CSF, IL-2, IL-7, IL-15, IP-10, MIP-1α, MIP-1β, MCP-1 |
| 37 | Human | Anti-PD-1 response prediction / NSCLC | Serum | IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 |
| 38 | Human | Immune thrombocytopenia / B regulatory cells | Serum | IL-10, TGF-β1, CD40, CD40L |
| 39 | Human | Pediatric food allergy | Serum | IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IFN-γ, TNF-α |
| 40 | Human | Papillary thyroid carcinoma / Hashimoto's | Serum | IL-10, IL-17, IL-35, IFN-γ |
| 41 | Human | HIV-1 / premature aging GNLY+CD8+ T cells | Plasma | MIG, IP-10, MCP-1, IL-6, IL-7, IL-12p70, IL-15, IL-18 |
| 42 | Human | Pemphigus foliaceus Th1/Th2/Th17 stratification | Plasma | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β |
| 43 | Human | Coronary artery disease / EV cargoes | Plasma | GDF-15 |
| 44 | Human | HIV-1 / GZMK+GZMB+CD8+ T cell subset | Plasma | sCD14, IP-10, MCP-1, IL-6, IL-7, IL-12p70, IL-15, IL-18, MIG, MIP-1β, RANTES |
| 45 | Human | Early breast cancer / circulating biomarkers | Plasma | Fractalkine, GRO-α, IP-10, TECK, TARC, IL-8, MCP-1, ITAC, BCA-1, RANTES, MIP-3β, CTACK, MIP-3α, 6-Ckine, CXCL12/SDF-1 |
| 46 | Human | Coronary calcium / GDF-15 in healthy aging | Plasma | GDF-15 |
| 47 | Human | Autism spectrum disorder / Th17 | Plasma | IL-2, IL-4, IL-5, IL-6, IL-10, IL-17A, TNF-α, IFN-γ, TGF-β1 |
| 48 | Human | Breast cancer / neuroinflammation post-chemo | Plasma | β-NGF, Eotaxin, IL-4, MIP-1β, VCAM-1, VEGF-A, BDNF, IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-18, MCP-1, TNF-α |
| 49 | Human | p75NTR / thrombo-inflammatory markers in aging | Plasma | BDNF, sCD40L, P-selectin |
| 50 | Human | BDNF / cognitive impairment | Plasma | BDNF, sP-selectin |
| 51 | Human | Luminal breast cancer / age-related immune remodeling | Plasma | IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-27, IP-10, MCP-1, TNF-α |
| 52 | Human | COVID-19 DAMPs profiling | Plasma | IL-1RA, MCP-1, MIP-1α, IP-10, IL-1β, IL-2, IL-6, IL-12p70, TNF-α, IFN-γ |
| 53 | Human | COVID-19 / MSC therapy phase 1 trial | Plasma | IL-6, IFN-γ, TNF-α, MCP-1, IP-10, IL-22, IL-1RA, IL-18, IL-8, MIP-1α |
| 54 | Human | COVID-19 / single-cell immune profiling | Plasma | IFN-γ, IL-6, IL-18, MCP-1, MIP-1α, IP-10 |
| 55 | Human | Critically ill children / IL-6 progression | Plasma | IL-2, IL-4, IL-6, IL-10, IL-17A, G-CSF, GM-CSF, TNF-α, TNF-β, IFN-γ |
| 56 | Human | Mild vs severe COVID-19 profiling | Plasma | IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β, IFN-γ, IL-1RA, IL-18, G-CSF, RANTES, MCP-1, IP-10, MIP-1α |
| 57 | Human | Dengue / NK cell activation | Plasma | IL-10, IL-15, IFN-γ |
| 58 | Human | Post-op critical patients / immune monitoring | Plasma | IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, TNF-α, TNF-β, G-CSF, GM-CSF |
| 59 | Human | HIV / atazanavir vs darunavir inflammation | Plasma | IL-6, MCP-1, sCD163, VCAM-1, adiponectin |
| 60 | Human | Atherothrombotic stroke / sCD137 | Plasma | sCD137 |
| 61 | Human | Adolescent fitness / cardio-metabolic risk | Plasma | IL-1β, IL-6, TNF-α, IL-10, CRP |
| 62 | Human | Olfactory–cognitive phenotype / aging 16-plex | Saliva | IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-27, IL-31, IL-33, IP-10, MCP-1, MIP-1α, TNF-α |
| 63 | Human | Dementia progression / oral microbiome | Saliva | IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-27, IL-31, IL-33, IP-10, MCP-1, MIP-1α, TNF-α |
| 64 | Human | Pediatric CNS angiostrongyliasis (Th1/Th2/Th17) | CSF | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β |
| 65 | Human | Febrile infection-related epilepsy / tocilizumab | Serum + CSF | IL-6 |
| 66 | Human | Severe viral encephalitis / refractory status epilepticus | Serum + CSF | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β |
| 67 | Human | Pediatric acquired demyelinating syndrome / NfL | Serum + CSF | TNF-β, IL-12p70, IL-1β, IL-10, IL-6, TNF-α, IFN-γ, IL-8, IL-4, IL-5, IL-17A, IL-22 |
| 68 | Human | Rasmussen's encephalitis | Brain tissue + CSF | IFN-γ, TNF-α, sCD137, GM-CSF, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-27, IL-31, IL-33, CXCL10, CCL2, CCL3, CCL4, CCL5, Granzyme B |
| 69 | Human | Proliferative diabetic retinopathy / DME | Vitreous | IL-1β, IL-6, IL-8, IL-27, TNF-α, ICAM-1, VCAM, MCP-1, VEGF-A, LCN2 (NGAL) |
| 70 | Human | Rhegmatogenous retinal detachment | Vitreous | Lipocalin-2 (LCN2/NGAL) |
| 71 | Human | Selective caries removal / dental biomarkers | Cavity rinse | MMP-7, MMP-8, MMP-9 |
| 72 | Human | Multiple myeloma / herpes zoster on bortezomib | Whole blood | IL-2, IL-10, TNF-α |
| 73 | Human | Platelet aggregation / BDNF | Platelets | IL-8, ENA-78, PF4, TARC, VEGF-A, VEGF-C, RANTES, PDGF-AB, SDF-1, ANGPT-1 |
| 74 | Human | Platelet differential secretion (large-scale) | Platelets | SDF-1, PDGF, VEGF-A, MIP-1α, RANTES, TARC, ENA-78, VEGF-C, IL-1α, IL-1β, IL-8, IL-33, MCP-1, ANGPT-1, Endostatin, PF4, IL-27, TNF-α |
| 75 | Human | Mastitis / breast milk profiling | Breast milk | IL-6, IL-8, TNF-α |
| 76 | Human | MIF / TEMPI syndrome | Serum + BM aspirates | MIF |
| 77 | Human | AML MSC-conditioned media / anti-leukemia | Cell culture supernatant | IFN-β, IFN-γ, IL-1β, IL-6, IL-8, IL-10, IL-17A, IL-18, IL-21, IL-22, IL-23, TNF-α |
| 78 | Human | RSV infection / selenomethionine | Cell culture supernatant | IL-1β, IL-6, IL-8, TNF-α, IFN-α |
| 79 | Human | Metastatic TAM / breast cancer modeling | Cell culture supernatant | VEGF-A, CXCL9, CCL5, CXCL11, CCL3, CXCL10, IL-6, IL-8, IL-10, IL-12p70, MCP-1, MMP-9, IL-1β, IL-23, TNF-α |
| 80 | Human | Adenovirus / selenomethionine JAK-STAT3 | Cell culture supernatant | IL-8, IL-10, IL-6, TNF-α, IFN-γ |
| 81 | Human | STAT3 inhibitor / senotherapeutic inflammation 11-plex | Cell culture supernatant | IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-27, IP-10, MCP-1, TNF-α |
| 82 | Human | NSCLC neoadjuvant / PBMC Th1/Th2/Th17 | PBMC supernatant | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β |
| 83 | Human | Influenza H1N1 / PEG-SeNPs | Cell culture supernatant | IL-1β, IL-5, IL-6, TNF-α |
| 84 | Human | Influenza / 5-nitrobenzo[c]selenadiazole | Cell culture supernatant | IL-12p70, IL-17F, TNF-α, TNF-β, IFN-γ |
| 85 | Human | Sjögren's / UC-MSC exosome immunomodulation | Cell culture supernatant | IFN-γ, TNF-α, IL-2, IL-4, IL-22, IL-6, IL-17A, IL-17F, IL-10, TGF-β |
| 86 | Human | Lupus / Helios+ Tfh cells | Cell culture supernatant | IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ |
| 87 | Human | HAdV-14 / selenocystine apoptosis | Cell culture supernatant | IL-6, IL-8 |
| 88 | Human | mTOR inhibitor / anti-aging screening 11-plex | Cell culture supernatant | IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-27, IP-10, MCP-1, TNF-α |
| 89 | Human | UV-B corneal damage / sulfonated DHPM | Cell culture supernatant | IL-6, IL-8, IL-10, VEGF-A |
| 90 | Human | COVID-19 associated mucormycosis | Serum | IL-1β, IFN-γ, IL-4, IL-6, IL-22, IL-17A, IL-10, IL-2, IL-12p70, IL-8, IL-7, IL-21, MCP-1, TNF-α, GM-CSF |
| 91 | Human | Aplastic anemia / pulmonary bacterial or fungal coinfection | Serum | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β |
| 92 | Human | Non-Hodgkin's lymphoma / respiratory bacterial infection diagnosis | Serum | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β |
| 93 | Human | Severe COVID-19 lung injury / placenta-derived MSC therapy | Serum | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-13, IL-6, IL-18, IL-10, IL-22, IL-17A, TNF-α |
| 94 | Human | Systemic sclerosis disease activity (fibrotic cytokines) | Serum | IL-1β, IL-4 |
| 95 | Human | IL-17 polymorphism / Greek asthma cohort | Serum | IL-6, IL-17A, IL-23, TGF-β1 |
| 96 | Human | GDF-15 as cardiology biomarker (review citation) | Serum (reference) | GDF-15 |
| 97 | Human | Recurrent implantation failure circulating immune profile (meta-analysis citation) | Serum (reference) | IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, TNF-α, TNF-β, G-CSF, GM-CSF |
| 98 | Human | Sandfly salivary protein immunomodulation 11-plex | Cell culture supernatant | TNF-α, IP-10, IL-1β, IL-27, IFN-γ, IL-8, IL-12p70, MCP-1, IL-1α, IL-6, IL-10 |
| 99 | Human | iPSC-derived macrophage differentiation | Cell culture supernatant | IL-6, IL-10, TNF-α |
| 100 | Human | Peroxiredoxin 6 / senescence-associated cytokines | Cell culture supernatant | IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-27, IP-10, MCP-1, TNF-α |
| 101 | Human | CAR-T (CD147) NSCLC therapy | Cell culture supernatant | IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α |
| 102 | Human | Cutaneous leishmaniasis vaccine candidates | Cell culture supernatant | IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α |
| 103 | Human | MSC / autoimmune hemolytic anemia | Cell culture supernatant | IL-2, IL-4, IL-10, IFN-γ, TNF-α, IL-17A |
| 104 | Human | Bath PUVA / keratinocyte chemokines | Cell culture supernatant | CCL21, CCL18, CCL19, CCL22, CCL27, CXCL2, CXCL12, CXCL16, CX3CL1 |
| 105 | Human | Chronic hepatitis B / Treg subpopulations | Cell culture supernatant | IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ |
| 106 | Human | Placental Hofbauer cells (GDM) | Hofbauer cell supernatant | Human 23-plex custom panel |
| 107 | Human | Hofbauer cell M2 polarization / angiogenesis | Cell culture supernatant | FGF-2, VEGF |
| 108 | Human | Colorectal cancer / Treg pro-tumor activity | Tissue-conditioned medium | IL-1β, IL-6, IL-23p19 |
| 109 | Human | CMV / glioma endocan | Cell culture supernatant | IFN-γ, IL-6, TNF-α |
| 110 | Human | Salvianolic acid B / endothelial inflammation | Cell culture supernatant | ICAM-1, IL-1β, IL-6, IL-8, MCP-1 |
| 111 | Human | NSCLC PD-L1 / CD137 ligand feedback | Cell culture supernatant | IFN-γ |
| 112 | Human | Lidocaine / postoperative recovery | Plasma cell culture media | IL-1RA, IL-6, IL-8 |
| 113 | Human | MSC IGF axis / Treg induction | BM-derived hMSC cultures | IGF-1, IGF-2 |
| 114 | Human | CAR-T CRS monitoring (24-plex Panel 1) | Serum | IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, TNF-α, TNF-β |
| 115 | Human | CAR-T CRS monitoring (24-plex Panel 2) | Serum | sCD25, GM-CSF, IL-15, MCP-1, Granzyme B, Reg3A, ST2, TNFRSF1A, Elafin, MIP-1α |
| 116 | Human | COVID-19 severity / 18-plex inflammation | Serum | IFN-γ, IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-27, IL-31, IL-33, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α |
| 117 | Human | COVID-19 severity / chemokine 7-plex | Serum | IP-10, I-TAC, MIP-1α, MIP-1β, 6Ckine, MDC, MIP-3β |
| 118 | Human | Virtual memory CD8+ T cells / HIV-1 ART | Serum | IL-1β, IP-10, I-TAC, MIG, IL-15, MCP-1, sCD14, IL-6, IFN-α2, MIP-1β, G-CSF, sCD163 |
| 119 | Human | Ulcerative colitis / fecal microbiota transplant 41-plex | Serum | IL-1α, IL-1RA, IL-12/IL-23p40, IL-12p70, IL-17C, IL-17F, TNF-α, IL-1β, IFN-γ, IL-23, IL-2, IL-6, IL-7, IL-15, IL-17A, IL-13, IL-4, IL-10, IFN-α, IP-10, MCP-1, MEC, MIP-1α, ENA-78, IL-8, RANTES, IL-5, G-CSF, FGF2, sIL-2R, IL-16, IL-22, EGF, CD40, 6CKine, BCA-1, TECK, E-selectin, P-selectin, ICAM-1, VCAM-1 |
| 120 | Human | Th1/Th2/Th17/Th9 18-plex profiling (customer-validated on CytoFlex) | Serum | IL-1β, IL-5, IL-12p70, IL-17F, IL-22, TNF-β, IL-2, IL-4, IL-17A, IL-8, IFN-γ, IL-10, IL-6, TNF-α, GM-CSF, IL-9, IL-33, TSLP |
| 121 | Human | Chemokine + inflammation 24-plex (customer-validated on CytoFlex, n=76 samples) | Serum | I-309, IL-1β, IL-10, IP-10, MIP-5, TNF-α, IL-2, IL-1RA, IFN-γ, IL-8, MIG, IL-12p70, MCP-1, TARC, I-TAC, IL-4, IL-5, IL-6, IL-17A, IL-13, IL-18, IL-33, CXCL16, MCP-4 |
| 122 | Mouse | Pneumococcal disease / coenzyme Q6 variant | Plasma / BAL fluid | CXCL2, CCL3, CCL4, IL-6, IL-12p70, CXCL10, CCL5, IL-13, CXCL1, IL-9, IL-1β, TNF-α, IL-1α, IFN-γ, IL-10 |
| 123 | Mouse | Polydatin + hawthorn / atherosclerosis | Serum | IL-1β, IL-2, IL-6, IL-17A, TNF-α, CRP |
| 124 | Mouse | Diabetic glomerulopathy / M2 macrophage infusion | Serum | IL-1β, MCP-1, IL-6, TNF-α |
| 125 | Mouse | Maternal TLR7 activation / behavior | Plasma | IFN-γ, IL-6, IL-10, IL-17A, TNF-α, IL-1β |
| 126 | Mouse | Cirrhosis LSECtin / 16-plex inflammation | Cell culture supernatant | CCL4, TNF-α, IL-1β, IL-12p70, IL-9, CXCL10, IL-1α, CCL3, IL-10, CXCL1, IL-13, CCL5, IL-6, IFN-γ, IL-15, CCL2 |
| 127 | Mouse | IBD / myocardial infarction (Th1/Th2/Th17 7-plex) | Serum | IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α |
| 128 | Mouse | Retinal ischemia/reperfusion / ciclopirox olamine | Cell culture supernatant | IL-1β, IL-6, IL-10, IL-17A, IL-22, IL-23, IFN-γ, TNF-α |
| 129 | Mouse | Renal ciliopathies / cell death | Kidney tissue lysate | IL-1α/IL-1F1, IL-1β, TNF-α, IL-33, IL-6, IL-10, IL-22, IFN-γ, MCP-1, IP-10/CXCL10 |
| 130 | Mouse | Brown rice bioactives / Nrf2 immunity 17-plex | Cell culture supernatant | GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-22, KC, TNF-α, TSLP |
| 131 | Mouse | Maternal intermittent fasting / gut barrier | Intestinal tissue extract | GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-22, IL-23, KC, TNF-α, TSLP |
| 132 | Mouse | IL-1RN / myeloproliferation | BM extracellular fluid | IL-1RN |
| 133 | Mouse | Systemic inflammation / hippocampal microglia (5-plex) | Plasma | IL-1β, IL-6, IL-10, MCP-1, TNF-α |
| 134 | Mouse | Curcumin / experimental multiple sclerosis | Cell culture supernatant | IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α |
| 135 | Mouse | NMN / sepsis macrophage reprogramming | Cell culture supernatant | IL-6, IL-10, IL-12p70, TNF-α |
| 136 | Mouse | Dermatitis / male infertility cytokines | Epididymal suspension | TNF-α, IL-1β, IL-12p70, MCP-1, IFN-γ, IL-6, KC, IL-10, IL-1α, IP-10, IL-23 |
| 137 | Mouse | Systemic inflammation / mixed AD-like pathology | Plasma | IL-6, IL-10, MCP-1, TNF-α |
| 138 | Mouse | Japanese encephalitis / Axl neuroinvasion | Serum | IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, CCL2, CCL5 |
| 139 | Mouse | Rice endosperm / gut microbiota & obesity | Serum + kidney/liver lysate | TNF-α, IL-1β, IL-6, MCP-1 |
| 140 | Mouse | Adipose-derived skin flap viability | Tissue lysate | TNF-α, IFN-γ, IL-6, VEGF |
| 141 | Mouse | Lipofuscin / microglial stimulation 17-plex | Cell culture supernatant | IFN-γ, IL-1α, IL-1β, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-23p19, IP-10, KC, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α |
| 142 | Mouse | Type 2 diabetes / UC-MSC macrophage polarization | Serum + cell culture supernatant | MCP-1, IL-1β, IL-4, IL-6, IL-10, TNF-α |
| 143 | Mouse | C. albicans vaginal infection / ATG5 KO | Vaginal lavage | G-CSF, IL-1α, IL-1β, IL-6, IL-10, IL-17A, IL-22, IL-23p19, TNF-α |
| 144 | Mouse | Ephedra Aconite Asarum / dendritic cells | BM-DC supernatant | IL-12, IFN-γ, IL-6, IL-1β, IL-4, IL-13 |
| 145 | Mouse | Aplastic anemia / Danggui Buxue Tang | Peripheral blood | IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-17A |
| 146 | Mouse | Mammary gland infection / proIL-1β | Mammary gland lysate + serum | KC, MIP-2 |
| 147 | Mouse | RIPK1 knockdown / immune-mediated liver injury | Serum | CXCL1, CXCL2, IFN-γ, IL-6, IL-17A, TNF-α |
| 148 | Mouse | Silica nanoparticle / lung inflammation | Serum | IL-1β, IL-18, TNF-α, IL-6 |
| 149 | Mouse | Berberine / ox-LDL inflammation 17-plex | Cell culture supernatant | IFN-γ, IL-1α, IL-1β, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-23, IP-10, KC, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α |
| 150 | Mouse | IL-7Rα / T cell homeostasis | Serum | IL-7, IL-7Rα/sCD127 |
| 151 | Mouse | Hepatocellular carcinoma xenograft characterization | Serum | Human AFP (xenograft model) |
| 152 | Rat | UDCA / liver inflammation (LPS) | Plasma | TNF-α, GM-CSF, IL-2, IFN-γ, IL-6, IL-1β |
| 153 | Rat | Colorectal peritoneal carcinomatosis / regorafenib | Serum | IL-6, TNF-α |
| 154 | Rat | Spinal cord injury / adipose MSC transplantation | Cell culture supernatant | IL-1β, IL-6, IL-10, TNF-α, IFN-γ, VEGF-A, BDNF, β-NGF/NGFB, PDGF-AB, PDGF-BB, FGF basic, CCL2, CCL5, CCL7, CXCL1, CXCL10, CXCL12 |
| 155 | Rat | UTI therapy / cerebral injury post-CA/ROSC | Serum | IL-6, TNF-α |
| 156 | Rat | Fecal microbiota transplant / depression | Hippocampus + serum | IL-4, IL-10, TNF-α, IL-1β, IL-2, IL-6, IL-17A, IFN-γ |
| 157 | Rat | Collagen-induced arthritis / UC-MSC EVs | Serum | IL-17, IL-10, TGF-β |
| 158 | Rat | HIF-1α/2α / stroke remote ischemic preconditioning | Peripheral blood + brain tissue | IL-1β, IL-6, TNF-α, IFN-γ, IL-4, IL-10 |
| 159 | Rat | High-calorie diet / LPS pneumonia | Tissue lysate | IL-6, IL-12p40, KC, TNF-α |
| 160 | Rat | Adipose-derived stem cell migration / allograft survival | Plasma | IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ |
| 161 | Rat | Particulate matter / CSF inflammation biomarker | Serum | IL-4, IL-6, IL-10, TNF-α |
| 162 | Rat | Yinlai decoction / LPS pneumonia in juveniles | Serum | IL-6, TNF-α, IL-12p40, IL-8 |
| 163 | Rat | Probiotic L. rhamnosus / colorectal ACF | Serum | IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, TNF-α |
| 164 | Rat | Jiayan Kangtai / autoimmune thyroiditis | Plasma | IL-2, IL-6, IL-10, IL-17A, TGF-β1 |
| 165 | Rat | Traffic PM exposure / brain impairment | Plasma | CCL5, CCL11, IL-4, IL-6 |
| 166 | Rat | HIF-1α / stroke preconditioning | Plasma | IFN-γ, IL-1β, IL-4, IL-6, IL-10 |
| 167 | Rat | Folate-NP endocytosis / Kupffer cells | Kupffer cells (culture) | TNF-α, IL-1β, IL-6 |
| 168 | Rat | Huang Lian Jie Du / inflammation PK-PD | Plasma | IFN-γ, IL-6, IL-1β, MIP-2, TNF-α, IL-13, IL-10 |
| 169 | Rat | Dampness-Heat / DMBA mammary tumors | Serum + tumor tissue | TNF-α, IL-1β |
| 170 | Rat | Tibia metastatic cancer pain / gabapentin | Tissue lysate | IL-12p70, IFN-γ, β-NGF |
Notes on use
- All panels listed have been used successfully on the indicated sample type. Sample preparation requirements (dilution factors, matrix effects, freeze-thaw stability) vary by analyte — consult the product insert for each panel.
- Custom panel configurations can be assembled from any validated analyte combination within the same species and detection chemistry. Contact your account representative for custom panel quoting.
- Cross-reactivity has been validated within species. Cross-species use of human panels on mouse/rat samples (or vice versa) is not recommended without prior validation.
- GeniePlex is for Research Use Only and not for diagnostic procedures.
- Preprints (Al-Hourani 2021, Spindola 2025, Da Silva 2025) reflect data shared before peer review; readers should consult the latest version of each preprint for updates.